Celltrion and Kaigene sign $580m licence deal for KG013
Celltrion and Kaigene sign $580m licence deal for KG013
Celltrion has acquired exclusive global development and commercialisation rights to Kaigene's investigational monoclonal antibody, KG013, in a deal worth up to $580m.